Almirall and Forest Announce Positive Results from the ATTAIN Phase III Study of Aclidinium Bromide and the Phase IIb Studies with the Fixed Dose Combination with Formoterol in Moderate to Severe COPD Patients - Drugs.com MedNews
Links shared publicly online about this topic.
- 603total visits
Almirall and Forest Announce Positive Results from the ATTAIN Phase III Study of Aclidinium Bromide and the Phase IIb Studies with the Fixed Dose Combination with Formoterol in Moderate to Severe COPD Patients - Drugs.com MedNews
Jan 4, 2011 - Almirall, S.A. (ALM.MC) and Forest Laboratories, Inc. (NYSE FRX) today announced positive top-line results of ATTAIN, a six month double-blind pla
View full resource at drugs.com
Tags: COPD, Drug, Forest Laboratories
Most Recently Shared on January 5, 2011 at 3:16 pm By:
Almirall and Forest Announce Positive Results from the ATTAIN Phase III Study of Aclidinium Bromide and th... http://bit.ly/gsEsID #drug
Advertisement
